Copper-based therapeutics : creating a formulation platform to facilitate development of an emerging drug class

................................................................................................................................................................... ii Lay Summary: ........................................................................................................................................................ iii Preface:..................................................................................................................................................................... iv Table of

[1]  V. S. Periasamy,et al.  Mixed-ligand copper(II)-phenolate complexes: effect of coligand on enhanced DNA and protein binding, DNA cleavage, and anticancer activity. , 2007, Inorganic chemistry.

[2]  G. Brewer.  Anticopper therapy against cancer and diseases of inflammation and fibrosis. , 2005, Drug discovery today.

[3]  M. Iskra,et al.  Analysis of serum copper and zinc concentrations in cancer patients , 2007, Biological Trace Element Research.

[4]  T. Meade.  Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. , 1975, British journal of preventive & social medicine.

[5]  I. Nakano,et al.  Senescence from glioma stem cell differentiation promotes tumor growth. , 2016, Biochemical and biophysical research communications.

[6]  Gregory I. Elliott,et al.  Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1 , 2009, Clinical Cancer Research.

[7]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[8]  L. Pickart,et al.  GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration , 2015, BioMed research international.

[9]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[10]  R. Hannan,et al.  Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.

[11]  M. Hiromura,et al.  Suppressive effect of orally administered copper(II)‐aspirinate (Cu2(asp)4) complex on the generation of reactive oxygen species in the skin of animals subjected to UVA exposure , 2007, Experimental dermatology.

[12]  M. Bally,et al.  pH gradients and membrane transport in liposomal systems. , 1991, Trends in biotechnology.

[13]  M. Bally,et al.  Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice , 2006, Molecular Cancer Therapeutics.

[14]  M. Bally,et al.  Copper-topotecan complexation mediates drug accumulation into liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Yanli Hao,et al.  Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  Ya Hui Hung,et al.  Role of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis , 2013, Front. Aging Neurosci..

[17]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[18]  L. Kay,et al.  Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma , 2009, Leukemia.

[19]  H. Farshad,et al.  Generation of Cisplatin-Resistant Ovarian Cancer Cell Lines , 2016 .

[20]  G. Rubini,et al.  The Copper Radioisotopes: A Systematic Review with Special Interest to 64Cu , 2014, BioMed research international.

[21]  B. S. Sekhon,et al.  Transition metal-based anti-malarial , 2012 .

[22]  Reena Gupta,et al.  Application of Liposomes in Treatment of Rheumatoid Arthritis: Quo Vadis , 2014, TheScientificWorldJournal.

[23]  R. Mumper,et al.  Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. , 2009, Cancer treatment reviews.

[24]  B. Nair,et al.  Antibacterial activity of copper(II) complexes against Staphylococcus aureus , 2014 .

[25]  Michael B Hursthouse,et al.  Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex. , 2007, Journal of inorganic biochemistry.

[26]  L. Martins,et al.  Diethyldithiocarbamate complexes with metals used as food supplements show different effects in cancer cells , 2014 .

[27]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[28]  Yihui Deng,et al.  Preparation of berberine hydrochloride long-circulating liposomes by ionophore A23187-mediated ZnSO4 gradient method , 2013 .

[29]  Aamir Ahmad,et al.  Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. , 2009, Mutagenesis.

[30]  F. Chang,et al.  Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation , 2002, Anti-cancer drugs.

[31]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[32]  M. Bally,et al.  Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. , 2007, Biochimica et biophysica acta.

[33]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[34]  D. Thiele,et al.  The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. , 2015, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[35]  Jennifer Stine Elam,et al.  Copper chaperones. , 2002, Advances in protein chemistry.

[36]  F. Tuna,et al.  On the interaction of copper(II) with disulfiram. , 2014, Chemical communications.

[37]  M. Bally,et al.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. , 1985, Biochimica et biophysica acta.

[38]  Jun Lu.  Triethylenetetramine Pharmacology and Its Clinical Applications , 2010, Molecular Cancer Therapeutics.

[39]  마크 이. 헤이스,et al.  Remote loading of sparingly water-soluble drugs into liposomes , 2014 .

[40]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[41]  P. Cullis,et al.  Developments in liposomal drug delivery systems , 2001, Expert opinion on biological therapy.

[42]  Q. Dou,et al.  Novel 8-hydroxylquinoline analogs induce copper-dependent proteasome inhibition and cell death in human breast cancer cells. , 2009, International journal of oncology.

[43]  Jesse J. Suh,et al.  The Status of Disulfiram: A Half of a Century Later , 2006, Journal of clinical psychopharmacology.

[44]  P. Sadler,et al.  The structure of the antitumor complex cis-(diammino) (1,1-cyclobutanedicarboxylato)-Pt(II): X ray and nmr studies , 1980 .

[45]  T. Mikkelsen,et al.  Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. , 2005, Neuro-oncology.

[46]  J. A. Shabbits,et al.  Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[47]  C. Ling,et al.  Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. , 2005, Nuclear medicine and biology.

[48]  Bolin Liu,et al.  Anticancer activity of the antibiotic clioquinol. , 2005, Cancer research.

[49]  S. Weiss,et al.  Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma , 2016, Clinical Cancer Research.

[50]  W. Shafer,et al.  Copper(II)-Bis(Thiosemicarbazonato) Complexes as Antibacterial Agents: Insights into Their Mode of Action and Potential as Therapeutics , 2015, Antimicrobial Agents and Chemotherapy.

[51]  Di Chen,et al.  Sodium diethyldithiocarbamate, an AIDS progression inhibitor and a copper-binding compound, has proteasome-inhibitory and apoptosis-inducing activities in cancer cells. , 2007, International journal of molecular medicine.

[52]  C. Masters,et al.  Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation , 2009, Proceedings of the National Academy of Sciences.

[53]  C. Supuran,et al.  Metal-Based Antibacterial and Antifungal Agents: Synthesis, Characterization, and In Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), and Zn(II) Complexes With Amino Acid-Derived Compounds , 2006, Bioinorganic chemistry and applications.

[54]  E. Jacobsen,et al.  A drug sensitizing the organism to ethyl alcohol. , 1948, Lancet.

[55]  Čeh,et al.  A Rigorous Theory of Remote Loading of Drugs into Liposomes: Transmembrane Potential and Induced pH-Gradient Loading and Leakage of Liposomes , 1997, Journal of colloid and interface science.

[56]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[57]  C. Marzano,et al.  Copper complexes as anticancer agents. , 2009, Anti-cancer agents in medicinal chemistry.

[58]  R. Reis,et al.  Liposomes in tissue engineering and regenerative medicine , 2014, Journal of The Royal Society Interface.

[59]  D. Thiele,et al.  Biochemical Characterization of the Human Copper Transporter Ctr1* , 2002, The Journal of Biological Chemistry.

[60]  K. Somasundaram,et al.  In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes. , 2013, Journal of medicinal chemistry.

[61]  D Needham,et al.  A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. , 2000, Cancer research.

[62]  Q. Dou,et al.  Molecular study on copper-mediated tumor proteasome inhibition and cell death. , 2010, International journal of oncology.

[63]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[64]  E. Shoubridge,et al.  Characterization of human SCO1 and COX17 genes in mitochondrial cytochrome-c-oxidase deficiency. , 2000, Biochemical and biophysical research communications.

[65]  L. Fishbein,et al.  Stability of sodium diethyldithiocarbamate in aqueous solution by proton magnetic resonance spectroscopy. , 1970, Journal of agricultural and food chemistry.

[66]  Wahid Khan,et al.  Liposomal Formulations in Clinical Use: An Updated Review , 2017, Pharmaceutics.

[67]  M. Tegoni,et al.  Copper-dependent cytotoxicity of 8-hydroxyquinoline derivatives correlates with their hydrophobicity and does not require caspase activation. , 2012, Journal of medicinal chemistry.

[68]  M. Merkx,et al.  Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. , 2007, The Biochemical journal.

[69]  R. Abdel-Rahman,et al.  Effect of a topical copper indomethacin gel on inflammatory parameters in a rat model of osteoarthritis , 2015, Drug design, development and therapy.

[70]  P. A. Lay,et al.  Anti-Inflammatory Dinuclear Copper(II) Complexes with Indomethacin. Synthesis, Magnetism and EPR Spectroscopy. Crystal Structure of the N,N-Dimethylformamide Adduct. , 1999, Inorganic chemistry.

[71]  M. Schilsky.  Diagnosis and long-term management of Wilson disease. , 2007, Gastroenterology & hepatology.

[72]  D. Thiele,et al.  Copper: An essential metal in biology , 2011, Current Biology.

[73]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.

[74]  M. Sarkar,et al.  Spectroscopic studies of the binding of Cu(II) complexes of oxicam NSAIDs to alternating G-C and homopolymeric G-C sequences. , 2014, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[75]  A. Tulpule,et al.  Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). , 2009, Breast.

[76]  B. Cvek.  Proteasome inhibitors. , 2012, Progress in molecular biology and translational science.

[77]  Zhong-Ying Ma,et al.  A thiosemicarbazone copper(II) complex as a potential anticancer agent , 2015 .

[78]  P. Proksch,et al.  Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780 , 2016, Journal of Cancer.

[79]  Jason S. Lewis,et al.  Copper-64 Radiopharmaceuticals for Oncologic Imaging. , 2009, PET clinics.

[80]  S. Piperakis,et al.  Copper and Its Complexes in Medicine: A Biochemical Approach , 2011, Molecular biology international.

[81]  J. Greenstone.  Relevance , 2007 .

[82]  Ying Sun,et al.  Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells , 2010, JBIC Journal of Biological Inorganic Chemistry.

[83]  Ismail Hafez,et al.  Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[84]  B. Chopade,et al.  Novel broad-spectrum metal-based antifungal agents , 1991, Biology of Metals.

[85]  X. Bian,et al.  Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells , 2012, British Journal of Cancer.

[86]  P. A. Lay,et al.  Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized , 2002 .

[87]  M. Bally,et al.  Generation of multilamellar and unilamellar phospholipid vesicles , 1986 .

[88]  S. Lutsenko,et al.  Human copper transporters: mechanism, role in human diseases and therapeutic potential. , 2009, Future medicinal chemistry.

[89]  J. Rommens,et al.  The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene , 1993, Nature Genetics.

[90]  B. Wang,et al.  Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures , 2013, Experimental and therapeutic medicine.

[91]  C. Steidl,et al.  Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro , 2016, PloS one.

[92]  J. Calvert,et al.  Effects of the copper chelators diethyldithiocarbamate and bathocuproine sulfonate on interferon and its antiviral state. , 1990, Journal of interferon research.

[93]  D. Thiele,et al.  Mechanisms for copper acquisition, distribution and regulation. , 2008, Nature chemical biology.

[94]  J. Babich,et al.  The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells , 2013, The Journal of Nuclear Medicine.

[95]  Jie Zheng,et al.  Transient metals enhance cytotoxicity of curcumin: potential involvement of the NF-kappaB and mTOR signaling pathways. , 2010, Anticancer research.

[96]  M. Bally,et al.  Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. , 1989, Biophysical journal.

[97]  Q. Dou,et al.  A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases , 2014, Scientific Reports.

[98]  P. Crouch,et al.  Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor α Release from Macrophages , 2008, Journal of Pharmacology and Experimental Therapeutics.

[99]  T. Allen.  Liposomal drug formulations. Rationale for development and what we can expect for the future. , 1998, Drugs.

[100]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[101]  B. Paquette,et al.  Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model , 2015, Investigational New Drugs.

[102]  M. Bally,et al.  Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent , 2017, International journal of nanomedicine.

[103]  Virapong Prachayasittikul,et al.  Antimicrobial Activity of 8-Hydroxyquinoline and Transition Metal Complexes , 2013 .

[104]  A. Hamby,et al.  Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[105]  R. Perez-soler,et al.  Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. , 1990, Cancer research.

[106]  Yves Pommier,et al.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress , 2017, Nature Medicine.

[107]  I-Ming Chu,et al.  Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. , 2003, Journal of bioscience and bioengineering.

[108]  B. Creaven,et al.  Anticancer and antifungal activity of copper(II) complexes of quinolin-2(1H)-one-derived Schiff bases , 2010 .

[109]  V. Culotta,et al.  Copper Chaperones: Personal Escorts for Metal Ions , 2002, Journal of bioenergetics and biomembranes.

[110]  Giuseppe Di Fazio,et al.  Interaction between indomethacin and heavy metal ions in aqueous solution. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[111]  W. Ding,et al.  Metal ionophores – An emerging class of anticancer drugs , 2009, IUBMB life.

[112]  Lori A Rowe,et al.  DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae. , 2008, Free radical biology & medicine.

[113]  T. Buettner,et al.  Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[114]  K. Edwards,et al.  An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[115]  A. Kaiser,et al.  Long‐term Antabuse treatment: tolerance and reasons for withdrawal , 1992, Acta psychiatrica Scandinavica. Supplementum.

[116]  L. Wimmers,et al.  Copper Transport Across Pea Thylakoid Membranes , 2004, Plant Physiology.

[117]  D. Velmurugan,et al.  Targeting of DNA molecules, BSA/c-Met tyrosine kinase receptors and anti-proliferative activity of bis(terpyridine)copper(ii) complexes. , 2016, Dalton transactions.

[118]  S. Dasgupta,et al.  Complex formation of rutin and quercetin with copper alters the mode of inhibition of Ribonuclease A , 2011, FEBS letters.

[119]  S. K. Choudhuri,et al.  A Novel Copper Chelate Modulates Tumor Associated Macrophages to Promote Anti-Tumor Response of T Cells , 2009, PloS one.

[120]  S. Kaler.  Metabolic and Molecular Bases of Menkes Disease and Occipital Horn Syndrome , 1998, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[121]  Jae-Geun Yoon,et al.  High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells , 2012, Oncotarget.

[122]  Chun-Ming Huang,et al.  High throughput screening for drug discovery of autophagy modulators. , 2012, Combinatorial chemistry & high throughput screening.

[123]  O. Podhajcer,et al.  Level in Ehrlich Ascites Tumor Cells -Monophosphate ' :5 ' Lactate Production, and Cyclic Adenosine 3 Effect of Liposome-encapsulated Quercetin on DNA Synthesis, , 2013 .

[124]  John W. Ferkany,et al.  Receptor Binding , 2005 .

[125]  M. Bally,et al.  Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer , 2013, Investigational New Drugs.

[126]  Cheng Luo,et al.  Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. , 2015, Nature chemistry.

[127]  D. Kessissoglou,et al.  Quinolones and non-steroidal anti-inflammatory drugs interacting with copper(II), nickel(II), cobalt(II) and zinc(II): structural features, biological evaluation and perspectives. , 2013, Dalton transactions.

[128]  Xudong Huang,et al.  Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Aβ peptides , 2004, JBIC Journal of Biological Inorganic Chemistry.

[129]  H. Sakurai,et al.  Orally active antioxidative copper(II) aspirinate: synthesis, structure characterization, superoxide scavenging activity, and in vitro and in vivo antioxidative evaluations , 2005, JBIC Journal of Biological Inorganic Chemistry.

[130]  M. Piccart,et al.  Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  S. Kaler.  Inborn errors of copper metabolism. , 2013, Handbook of clinical neurology.

[132]  Ralph Weissleder,et al.  Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.

[133]  Anitha Thomas,et al.  Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation , 2006, Pharmaceutical Research.

[134]  P. Cullis,et al.  Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[135]  Tej B. Shrestha,et al.  Copper Complexation Screen Reveals Compounds with Potent Antibiotic Properties against Methicillin-Resistant Staphylococcus aureus , 2014, Antimicrobial Agents and Chemotherapy.

[136]  Yanjiang Wang,et al.  Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. , 2016, Current Alzheimer research.

[137]  M. Suwalsky,et al.  Cu2+ ions interact with cell membranes. , 1998, Journal of inorganic biochemistry.

[138]  K. Edwards,et al.  Nanoscale Reaction Vessels Designed for Synthesis of Copper-Drug Complexes Suitable for Preclinical Development , 2016, PloS one.

[139]  Q. Dou,et al.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. , 2010, Current medicinal chemistry.

[140]  A. Goldberg,et al.  The effect of sodium diethyldithiocarbamate treatment on copper and zinc concentrations in rat brain. , 1982, Toxicology and applied pharmacology.

[141]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[142]  K. Smith,et al.  A copper treatable Menkes disease mutation associated with defective trafficking of a functional Menkes copper ATPase , 2003, Journal of medical genetics.

[143]  P. Sadler,et al.  Ring-opening reactions of the anticancer drug carboplatin : NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5'-GMP-N7) in solution , 1993 .

[144]  Francesco Tisato,et al.  Copper in Diseases and Treatments, and Copper‐Based Anticancer Strategies , 2010 .

[145]  Di Chen,et al.  Novel metals and metal complexes as platforms for cancer therapy. , 2010, Current pharmaceutical design.

[146]  E. Boros,et al.  Imaging Tumor Vasculature Noninvasively with Positron Emission Tomography and RGD Peptides Labeled with Copper 64 Using the Bifunctonal Chelates DOTA, Oxo-DO3A. and PCTA , 2013, Molecular imaging.

[147]  S. Flora,et al.  Chelation in Metal Intoxication , 2010, International journal of environmental research and public health.

[148]  Daniel C. Hill,et al.  Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) Complexes , 2000 .

[149]  Lawrence Mayer,et al.  Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. , 2007, International journal of pharmaceutics.

[150]  E. Colado,et al.  The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype , 2008, Haematologica.

[151]  M. Bally,et al.  A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[152]  A. Schimmer.  Clioquinol - a novel copper-dependent and independent proteasome inhibitor. , 2011, Current cancer drug targets.

[153]  M. Agotegaray,et al.  Anti-nociceptive activity and toxicity evaluation of Cu(II)-fenoprofenate complexes in mice. , 2012, European journal of pharmacology.

[154]  M. Bally,et al.  The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.

[155]  F. Soncin,et al.  Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. , 1997, Biochemical and biophysical research communications.

[156]  A. Datti,et al.  Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy , 2015, Molecular oncology.

[157]  T. Boulikas,et al.  Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.

[158]  P. Diwan,et al.  Preparation and Pharmacodynamic Evaluation of Liposomes of Indomethacin , 2000, Drug development and industrial pharmacy.

[159]  Z. Dvořák,et al.  Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. , 2007, Current pharmaceutical design.

[160]  Dianne Ford,et al.  Metalloproteins and metal sensing , 2009, Nature.

[161]  David Holmes.  The problem with platinum. , 2015, Nature.

[162]  C. Colton,et al.  Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration. , 2013, Biomedical spectroscopy and imaging.

[163]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[164]  D. Thiele,et al.  Structure of the Ctr1 copper trans'PORE'ter reveals novel architecture. , 2006, Trends in biochemical sciences.

[165]  S. Sayen,et al.  A novel copper(II) mononuclear complex with the non-steroidal anti-inflammatory drug diclofenac: structural characterization and biological activity. , 2013, Journal of inorganic biochemistry.

[166]  R Laforest,et al.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[167]  P. Cullis,et al.  Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. , 1998, Biochimica et biophysica acta.

[168]  Jie Zheng,et al.  N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. , 2010, Cancer letters.

[169]  Daniel C. Hill,et al.  Synthesis and transition-metal complexes of new cross-bridged tetraamine ligands , 1996 .

[170]  A. Vlad,et al.  Cancer Management and Research Dovepress Targeted Treatment of Recurrent Platinum-resistant Ovarian Cancer: Current and Emerging Therapies , 2022 .

[171]  M. L’Abbé,et al.  Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. , 2008, The Biochemical journal.

[172]  James D Crapo,et al.  Extracellular Superoxide Dismutase and Risk of COPD , 2009, COPD.

[173]  A. G. Wedd,et al.  Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity. , 2008, Inorganic chemistry.

[174]  B. Andresen,et al.  The actions of metabolic fate of disulfiram. , 1981, Annual review of pharmacology and toxicology.

[175]  Howard L McLeod,et al.  Platinum neurotoxicity pharmacogenetics , 2009, Molecular Cancer Therapeutics.

[176]  M. Aschner,et al.  Metals and Neurodegeneration , 2016, F1000Research.

[177]  E. Efthimiadou,et al.  Mononuclear copper(II) complexes with quinolones and nitrogen-donor heterocyclic ligands: Synthesis, characterization, biological activity and interaction with DNA , 2007 .

[178]  R. Kast,et al.  Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition , 2013, Oncoscience.

[179]  S. Croft,et al.  Synthesis and characterization of copper(II) complexes of pyridine-2-carboxamidrazones as potent antimalarial agents , 2003 .

[180]  Quynh-Thu Le,et al.  Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.

[181]  B. Cvek,et al.  Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. , 2012, Mini reviews in medicinal chemistry.

[182]  W. Cai,et al.  In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3 , 2006 .

[183]  K. Blennow,et al.  Treatment of Alzheimer’s Disease with Clioquinol , 2001, Dementia and Geriatric Cognitive Disorders.

[184]  P. Wakeley,et al.  Synthesis , 2013, The Role of Animals in Emerging Viral Diseases.

[185]  Walter Schaffner,et al.  Copper homeostasis in eukaryotes: teetering on a tightrope. , 2006, Biochimica et biophysica acta.

[186]  A. Powell,et al.  Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[187]  Ayesha Khan,et al.  Synthesis and biological evaluation of copper(II) pyrenethiosemicarbazone , 2015 .

[188]  A. Bush,et al.  Increasing intracellular bioavailable copper selectively targets prostate cancer cells. , 2013, ACS chemical biology.

[189]  M. Marina,et al.  Spectrophotometric determination of copper(II), nickel(II), and cobalt(II) as complexes with sodium diethyldithiocarbamate in the anionic micellar media of dodecylsulfate salts , 1995 .

[190]  C. Saunders,et al.  The antifungal mechanism of action of zinc pyrithione , 2011, The British journal of dermatology.

[191]  Corrie Lynn Messerer,et al.  Liposomal Irinotecan , 2004, Clinical Cancer Research.

[192]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[193]  J. Peppercorn,et al.  The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene , 1993, Nature Genetics.

[194]  B. Desoize.  Metals and metal compounds in cancer treatment. , 2004, Anticancer research.

[195]  Anthony R. White,et al.  Copper complexes as therapeutic agents. , 2012, Metallomics : integrated biometal science.

[196]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[197]  M. Giorgetti,et al.  In vitro and in vivo anticancer activity of copper(I) complexes with homoscorpionate tridentate tris(pyrazolyl)borate and auxiliary monodentate phosphine ligands. , 2014, Journal of medicinal chemistry.

[198]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[199]  M. Welch,et al.  In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. , 2000, Bioconjugate chemistry.

[200]  S. Bareggi,et al.  Clioquinol: Review of its Mechanisms of Action and Clinical Uses in Neurodegenerative Disorders , 2012, CNS neuroscience & therapeutics.

[201]  P. Grigsby,et al.  An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix , 2008, Journal of Nuclear Medicine.

[202]  M. Bally,et al.  Uptake of safranine and other lipophilic cations into model membrane systems in response to a membrane potential , 1985 .

[203]  Krishna Bisetty,et al.  Dithiocarbamates as hazardous remediation agent: A critical review on progress in environmental chemistry for inorganic species studies of 20th century , 2014 .

[204]  Myriam Rochdi,et al.  Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.

[205]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer , 2013, The Journal of Nuclear Medicine.

[206]  Xu Zi-rong.  Intracellular Copper Routing:The Role of Copper Chaperones , 2004 .

[207]  O. Kutsch,et al.  8-Hydroxyquinolines Are Boosting Agents of Copper-Related Toxicity in Mycobacterium tuberculosis , 2016, Antimicrobial Agents and Chemotherapy.

[208]  W. Guida,et al.  Copper storage diseases: Menkes, Wilsons, and cancer. , 2004, Frontiers in bioscience : a journal and virtual library.

[209]  R. Siliciano,et al.  Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation , 2011, Journal of Virology.

[210]  A. Powell,et al.  Copper complexes of carboxamidrazone derivatives as anticancer agents. 3. Synthesis, characterization and crystal structure of [Cu(appc)Cl2], (appc=N1-(2-acetylpyridine)pyridine-2-carboxamidrazone) , 2001 .

[211]  A. Eastman,et al.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. , 1991, The Journal of clinical investigation.

[212]  S. Kaler.  Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. , 1998, The American journal of clinical nutrition.

[213]  J. Aldrich-Wright,et al.  The antimicrobial and antibiofilm activities of copper(II) complexes. , 2014, Journal of inorganic biochemistry.

[214]  M. Bally,et al.  PRCosomes: pretty reactive complexes formed in liposomes , 2016, Journal of drug targeting.

[215]  P. Yogeeswari,et al.  Camptothecin and its analogues: a review on their chemotherapeutic potential , 2005, Natural product research.

[216]  M. Bally,et al.  The Role of the Transition Metal Copper and the Ionophore A23187 in the Development of Irinophore C™ , 2011, Pharmaceutical Research.

[217]  Hong Liang,et al.  Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin. , 2015, Journal of inorganic biochemistry.

[218]  M. Bally,et al.  Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. , 1988, Chemistry and physics of lipids.

[219]  D. Kovala-Demertzi,et al.  Transition metal complexes of diclofenac with potentially interesting anti-inflammatory activity. , 2000, Journal of inorganic biochemistry.

[220]  V. Malatesta,et al.  Chelation of copper(II) ions by doxorubicin and 4′-epidoxorubicin: ESR evidence for a new complex at high anthracycline/copper molar ratios , 1987 .

[221]  J. Mellors,et al.  Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog , 2013, AIDS.

[222]  Haiyuan Zhang,et al.  Potent anticancer activity of pyrrolidine dithiocarbamate–copper complex against cisplatin-resistant neuroblastoma cells , 2008, Anti-cancer drugs.

[223]  K. Daniel,et al.  Anti-angiogenic and anti-tumor properties of proteasome inhibitors. , 2005, Current cancer drug targets.

[224]  D. Thiele,et al.  A delicate balance: homeostatic control of copper uptake and distribution. , 1999, The Journal of nutrition.

[225]  S. Stănilă,et al.  Antibacterial Activity of Copper and Cobalt Amino Acids Complexes , 2011 .

[226]  K. Daniel,et al.  Cellular and computational studies of proteasome inhibition and apoptosis induction in human cancer cells by amino acid Schiff base-copper complexes. , 2013, Journal of inorganic biochemistry.

[227]  A. Camins,et al.  Current Research Therapeutic Strategies for Alzheimer's Disease Treatment , 2016, Neural plasticity.

[228]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[229]  L. Mayer,et al.  Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. , 1985, Biochimica et biophysica acta.

[230]  M. Bally,et al.  Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. , 1990, Biochimica et biophysica acta.

[231]  Guojun Wu,et al.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. , 2010, Cancer research.

[232]  S. Radulović,et al.  Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids. , 2015, Dalton transactions.

[233]  Di Chen,et al.  Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells , 2005, Breast Cancer Research.

[234]  Paweł Szymański,et al.  Development of copper based drugs, radiopharmaceuticals and medical materials , 2012, BioMetals.

[235]  S. Knapp,et al.  Copper is required for oncogenic BRAF signaling and tumorigenesis , 2013, Nature.

[236]  H. Kodama,et al.  Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment , 2012, Current drug metabolism.

[237]  M. Bally,et al.  Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol) , 2002, Bioscience reports.

[238]  M. Harada,et al.  Wilson disease , 2002, Medical Electron Microscopy.

[239]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[240]  L. Rybak,et al.  Cisplatin ototoxicity and protection: clinical and experimental studies. , 2009, The Tohoku journal of experimental medicine.

[241]  E. Shoubridge,et al.  The human cytochrome c oxidase assembly factors SCO1 and SCO2 have regulatory roles in the maintenance of cellular copper homeostasis. , 2007, Cell metabolism.

[242]  Luming Liu,et al.  A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts. , 2013, Toxicology and applied pharmacology.

[243]  P. Sharp.  Ctr1 and its role in body copper homeostasis. , 2003, The international journal of biochemistry & cell biology.

[244]  Hui-Bie F. Xu,et al.  DNA damage by copper(II) complexes: coordination-structural dependence of reactivities. , 1999, Journal of inorganic biochemistry.

[245]  J. Menkes.  Menkes disease and Wilson disease: two sides of the same copper coin. Part I: Menkes disease. , 1999, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[246]  P. Cremer,et al.  Phosphatidylserine reversibly binds Cu2+ with extremely high affinity. , 2012, Journal of the American Chemical Society.

[247]  M. Minden,et al.  A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. , 2012, Clinical lymphoma, myeloma & leukemia.

[248]  Svetlana Lutsenko,et al.  Function and regulation of human copper-transporting ATPases. , 2007, Physiological reviews.

[249]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[250]  J. Hanson,et al.  STRUCTURE OF A COPPER‐ISONIAZID COMPLEX , 1982 .

[251]  H. Prentice,et al.  Lipid-based amphotericin B: a review of the last 10 years of use. , 2001, International journal of antimicrobial agents.

[252]  Bing-Zhong Xu,et al.  Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. , 2010, Cancer letters.

[253]  M. Pegram,et al.  Platinum–Taxane Combinations in Metastatic Breast Cancer: An Evolving Role in the Era of Molecularly Targeted Therapy , 2004, Breast Cancer Research and Treatment.

[254]  H. Nichol,et al.  The solution structure of the copper clioquinol complex. , 2014, Journal of inorganic biochemistry.

[255]  Carolyn J Anderson,et al.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. , 2009, Cancer biotherapy & radiopharmaceuticals.

[256]  A. Ghavamzadeh,et al.  Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations , 2016, Journal of Nanobiotechnology.

[257]  V. Prachayasittikul,et al.  8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications , 2013, Drug design, development and therapy.

[258]  R. Maccari,et al.  Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9. , 2000, Bioorganic & medicinal chemistry letters.

[259]  S. Lippard,et al.  Understanding and improving platinum anticancer drugs--phenanthriplatin. , 2014, Anticancer research.

[260]  Li‐Min Liu,et al.  Cytotoxicity of the traditional chinese medicine (TCM) plumbagin in its copper chemistry. , 2009, Dalton transactions.

[261]  Huiqi Xie,et al.  Role of copper in angiogenesis and its medicinal implications. , 2009, Current medicinal chemistry.

[262]  J. Cobby,et al.  The rapid reduction of disulfiram in blood and plasma. , 1977, The Journal of pharmacology and experimental therapeutics.

[263]  I. Turel,et al.  Interaction of copper(II) with the non-steroidal anti-inflammatory drugs naproxen and diclofenac: synthesis, structure, DNA- and albumin-binding. , 2011, Journal of inorganic biochemistry.

[264]  Roger Lecomte,et al.  Standardization and Detailed Characterization of the Syngeneic Fischer/F98 Glioma Model , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[265]  Adam Siddiqui-Jain,et al.  Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. , 2012, ACS medicinal chemistry letters.

[266]  H. Gali-Muhtasib,et al.  Copper chelation selectively kills colon cancer cells through redox cycling and generation of reactive oxygen species , 2014, BMC Cancer.

[267]  Shanshan Zhu,et al.  Active loading liposomal irinotecan hydrochloride: Preparation, in vitro and in vivo evaluation , 2013 .

[268]  M. Pathak,et al.  Evaluation of DNA/Protein interactions and cytotoxic studies of copper(II) complexes incorporated with N, N donor ligands and terpyridine ligand. , 2017, International Journal of Biological Macromolecules.

[269]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[270]  M. Christian,et al.  New Cisplatin Analogues in Development , 1993, Drugs.

[271]  T. Irving,et al.  Synchrotron X‐ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity , 2009, Journal of cellular biochemistry.

[272]  Y. Yonekura,et al.  Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. , 1999, Nuclear medicine and biology.

[273]  Christopher Rensing,et al.  Metallic Copper as an Antimicrobial Surface , 2010, Applied and Environmental Microbiology.

[274]  P. Liu,et al.  The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells , 2015, Toxicology research.

[275]  M. Bally,et al.  Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[276]  D. Mellor,et al.  Order of Stability of Metal Complexes , 1948, Nature.

[277]  Hongmei Shen,et al.  Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells. , 2014, Biochemical and biophysical research communications.

[278]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[279]  S. Hersch,et al.  Mechanisms of Copper Ion Mediated Huntington's Disease Progression , 2007, PloS one.

[280]  J. Prohaska,et al.  Role of copper transporters in copper homeostasis. , 2008, The American journal of clinical nutrition.

[281]  Y. Kumagai,et al.  Copper diethyldithiocarbamate as an activator of Nrf2 in cultured vascular endothelial cells , 2016, JBIC Journal of Biological Inorganic Chemistry.

[282]  B. Johansson.  A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites , 1992, Acta psychiatrica Scandinavica. Supplementum.

[283]  P. Dent,et al.  Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. , 2004, Blood.

[284]  T. Hoogenraad.  Paradigm shift in treatment of Wilson's disease: Zinc therapy now treatment of choice , 2006, Brain and Development.

[285]  W. Ding,et al.  Nitroxoline ( 5-amino-8-hydroxyquinoline ) is more a potent anti-cancer agent than clioquinol ( 5-chloro-7-iodo-8-quinoline ) , 2012 .

[286]  J. R. Lou,et al.  Clioquinol independently targets NF-kappaB and lysosome pathways in human cancer cells. , 2010, Anticancer research.

[287]  S. Okuyama,et al.  Copper complexes of non-steroidal antiinflammatory agents: Analgesic activity and possible opioid receptor activation , 1987, Agents and Actions.

[288]  S. Bharti,et al.  Metal Based Drugs: Current Use and Future Potential , 2009 .

[289]  A. Gabizon,et al.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. , 1989, Journal of the National Cancer Institute.

[290]  M. Bally,et al.  Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors , 2008, Clinical Cancer Research.

[291]  M. Roch-Arveiller,et al.  Non-steroidal anti-inflammatory drug-copper complex modulation of polymorphonuclear leukocyte migration. , 1990, Biochemical pharmacology.

[292]  V. Gandin,et al.  Advances in copper complexes as anticancer agents. , 2014, Chemical reviews.

[293]  P. Cullis,et al.  Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. , 1998, Biochimica et biophysica acta.

[294]  P. A. Lay,et al.  Determination of the structures of antiinflammatory copper(II) dimers of indomethacin by multiple-scattering analyses of X-ray absorption fine structure data. , 2001, Inorganic chemistry.

[295]  T. Hambley,et al.  Copper(II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. , 1996, Journal of inorganic biochemistry.

[296]  K. Franz,et al.  Pharmacological activity of metal binding agents that alter copper bioavailability. , 2015, Dalton transactions.

[297]  W. Guida,et al.  Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. , 2004, Biochemical pharmacology.

[298]  Disulfiram , 2018, Reactions Weekly.